Last reviewed · How we verify
NCT06857487: QUIET
Qingre Huatan Formula for the Prevention of Early Neurological Deterioration in Acute Ischemic Stroke
Phase 1, PHASE2 trial testing Qingre Huatan Formula in Acute Ischemic Stroke in 72 participants. Currently enrolling.
24 October 2026
Quick facts
| Lead sponsor | Dongzhimen Hospital, Beijing |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 72 |
| Start date | 13 June 2025 |
| Primary completion | 24 October 2026 |
| Estimated completion | 29 October 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Qingre Huatan Formula — full drug profile →
- Qingre Huatan Formula placebo
- Guidelines-based standard care
Conditions studied
- Acute Ischemic Stroke — all drugs for Acute Ischemic Stroke →
Sponsor
Dongzhimen Hospital, Beijing
Who can join
Adults 18 to 80, any sex, with Acute Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to assess the effectiveness and safety of Qingre Huatan formula versus placebo on preventing early neurological deterioration in patients with acute ischemic stroke within 48 hours after onset.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Efficacy and safety of Qingre Huatan Formula for the prevention of early neurological deterioration in patients with acute ischemic stroke (QUIET): rationale and design for a randomized double-blind placebo-controlled study.
Zheng X, Yang Z, Wu H, Zhao M, et al · · 2026 · PMID 42051694 · DOI 10.3389/fmed.2026.1754648
Verify or expand the search:
- PubMed search for NCT06857487
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Ischemic Stroke
Currently open trials in the same condition.
- NCT07115940 — Medical Management With Endovascular Thrombectomy Versus Medical Management Alone in Patients Presenting Beyond 24 Hours · NA · recruiting
- NCT07404852 — Non-invasive Vagus Nerve Stimulation to Reduce Inflammation and Brain Injury Blood Biomarkers Following an Acute Ischemi · NA · recruiting
- NCT07361302 — A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Pe · Phase 3 · recruiting
- NCT07436156 — SUMMIT RISE Study of Acute Ischemic Stroke Patients · Phase 4 · recruiting
- NCT07203625 — Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours · Phase 4 · recruiting
Other Dongzhimen Hospital, Beijing trials
Trials by the same sponsor.
- NCT07271732 — Songling Xuemaikang Capsules for Cerebral Small Vessel Disease · NA · not yet recruiting
- NCT07342075 — Registry Study of Cerebral Small Vessel Disease · recruiting
- NCT07163702 — Efficacy and Safety of Xinglou Chengqi Granule for Acute Ischemic Stroke · Phase 2 · not yet recruiting
- NCT06933238 — Efficacy of Fuzheng Tongfu Jiedu Prescription for Treating Gastrointestinal Dysfunction Associated With Sepsis · Phase 1, PHASE2 · not yet recruiting
- NCT06686355 — The Treatment of Sepsis Induced Myocardial Dysfunction With Yiqilishui Formula · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06857487 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dongzhimen Hospital, Beijing
- Last refreshed: 1 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06857487.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing